Subtype
Uterine Neoplasm
CI-CAN-00004208Explore in graph →
Non-malignant925 active trials7 approved drugs44 evidence items
Loading cancer entity…
Subtype
CI-CAN-00004208Explore in graph →
Clinical trials
3,823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies(PETRA) | active not recruiting | Phase 1 / Phase 2 | 702 | AstraZenecaINDUSTRY | 14 | Sep 21, 2026 | clinicaltrials |
| NCT05237947 | Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial(PRISMA) | active not recruiting | Phase 4 | 5,000 | National Cancer Institute (NCI)NIH |
| 1 |
| Sep 21, 2026 |
| clinicaltrials |
| NCT05920798 | Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer(FRAPPE) | active not recruiting | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05983432 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | recruiting | Phase 1 | 540 | SystImmune Inc.INDUSTRY | 5 | Sep 21, 2026 | clinicaltrials |
| NCT06038032 | ImpRoving hEalth behaviourS for LIfe After ENdometrial CancEr Trial(RESILIENCE) | recruiting | N/A | 148 | University of AlbertaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06925724 | A Study of Ivonescimab in People With Endometrial and Cervical Cancers | recruiting | Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831902 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer(NSMP-ORANGE) | recruiting | Phase 3 | 600 | University College, LondonOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07832227 | Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial(SIERRA) | not yet recruiting | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT04038619 | Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients | recruiting | Phase 1 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04266886 | Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer | active not recruiting | N/A | 152 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04634877 | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | active not recruiting | Phase 3 | 990 | Merck Sharp & Dohme LLCINDUSTRY | 28 | Sep 18, 2026 | clinicaltrials |
| NCT05092022 | St. Joseph's HPV Self-sampling: Offering a Self-sampling Option in Clinic | active not recruiting | N/A | 50 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06714084 | CNCMT:a Multi-center, Prospective, Single-arm Study(CNCMT) | enrolling by invitation | N/A | 20 | Hubei Cancer HospitalOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07147361 | Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma(PB-PD1R-SCC) | active not recruiting | — | 800 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07810920 | Artificial Intelligence Into Ultrasound Diagnostics in Reproductive Medicine(AUDRIE) | recruiting | — | 1,600 | Semmelweis UniversityOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)(MK-2870-001) | active not recruiting | Phase 1 / Phase 2 | 1,410 | Klus Pharma Inc.INDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT05475171 | Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) | recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05758688 | PROton Therapy for Post Surgical Treatment of GYNecologic Cancer(PROPS GYN) | recruiting | Phase 2 | 25 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06340568 | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer(Fern-EC-01) | recruiting | Phase 3 | 480 | BioNTech SEINDUSTRY | 26 | Sep 17, 2026 | clinicaltrials |
| NCT06708351 | Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial | not yet recruiting | N/A | 2,280 | Emory UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06952504 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)(TroFuse-033) | recruiting | Phase 3 | 1,123 | Merck Sharp & Dohme LLCINDUSTRY | 34 | Sep 17, 2026 | clinicaltrials |
| NCT07020117 | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | recruiting | Phase 1 | 150 | Aktis Oncology, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | recruiting | Phase 1 / Phase 2 | 205 | Terremoto Biosciences Inc.INDUSTRY | 4 | Sep 17, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04604613 | Prediction of Recurrence Among Low Risk Endometrial Cancer Patients | active not recruiting | — | 518 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05677048 | Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention | active not recruiting | N/A | 205 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06366347 | ALPINE: Maintenance Letrozole/Abemaciclib | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06409052 | Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women | recruiting | — | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07116213 | Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer | recruiting | N/A | 20 | Xiaorong HouOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07584161 | MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer(ARTISAN) | recruiting | N/A | 228 | Xiaorong HouOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04073706 | Sentinel Node Biopsy in Endometrial Cancer(ENDO-3) | recruiting | Phase 3 | 760 | Queensland Centre for Gynaecological CancerOTHER_GOV | 7 | Sep 15, 2026 | clinicaltrials |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | recruiting | Phase 1 / Phase 2 | 300 | PMV Pharmaceuticals, IncINDUSTRY | 9 | Sep 15, 2026 | clinicaltrials |
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07341737 | SL-28 for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 60 | Second Life TherapeuticsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07807202 | Improving HPV Vaccination Coverage Among Adolescent Girls in Mali and Côte d'Ivoire Through Community Health Worker Follow-up | active not recruiting | N/A | 17,188 | Arsène Brunelle SandieOTHER | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07820358 | Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer(SWIFT) | not yet recruiting | Phase 2 | 48 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT00791635 | Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer | active not recruiting | — | 79 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04575935 | Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial | recruiting | Phase 3 | 580 | M.D. Anderson Cancer CenterOTHER | 5 | Sep 14, 2026 | clinicaltrials |
| NCT04723095 | Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix(NeCTuR) | recruiting | — | 750 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04977453 | GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 317 | GI Innovation, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation(ORACLE) | recruiting | — | 2,285 | Guardant Health, Inc.INDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT05799274 | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors(RAD301) | active not recruiting | Phase 1 | 9 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05123482 | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | recruiting | Phase 1 / Phase 2 | 460 | AstraZenecaINDUSTRY | 15 | Sep 11, 2026 | clinicaltrials |
| NCT05979493 | QL Block in Laparoscopic Myomectomy | recruiting | Phase 4 | 80 | Joseph Findley MDOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07065552 | Tirzepatide in Obesity-Driven Endometrial Cancer | recruiting | Early Phase 1 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07814872 | A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment(FATHOM) | not yet recruiting | — | 30,000 | Harvard Medical School (HMS and HSDM)OTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815873 | Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers(CERBERO) | not yet recruiting | N/A | 360 | European Institute of OncologyOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815951 | Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors | not yet recruiting | Phase 1 | 8 | Yong HeOTHER | 1 | Sep 11, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials